Juan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Juan Wang has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Guixiang Tai
Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China
11 shared publications Fei Xie
Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
8 shared publicationsHongyan Yuan
Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
8 shared publicationsQiongshu Li
Department of Immunology, College of Basic Medical Science, Jilin University, Changchun, Jilin 130021, P.R. China
8 shared publicationsTanxiu Chen
Department of Immunology, College of Basic Medical Science, Jilin University, Changchun 130021, China
7 shared publicationsRuiping Zhai
Department of Immunology, College of Basic Medical Science, Jilin University, Changchun, Jilin 130021, P.R. China
6 shared publications
Latest Publications
- Open Access
- 26 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (52) , e46846
Conservative treatment of giant spontaneous retropharyngeal hematoma: A case report
Rationale: Spontaneous retropharyngeal hematoma (SRH) is an occult disease that can cause rapid airway obstruction. Currently, no standardized diagnostic and therapeutic protocols have been established. In this case report, we present the successful conservative management of a patient with a giant SRH, further discuss strategies for airway management and hematoma evacuation, and intend to offer practical insights for the diagnosis and management of SRH. Patient concerns: A 54-year-old female patient with rapidly progressive neck swelling and respiratory tract obstruction. Diagnoses: The patient was diagnosed with SRH through computed tomography, magnetic resonance imaging, laryngoscope and ultrasound-guided aspiration biopsy. Interventions: Timely orotracheal intubation, tracheotomy, and anti-infective therapy. Outcomes: After these treatments, the patient successfully had the tracheostomy tube removed after 4 weeks and was discharged from the hospital upon recovery. Lessons: This case emphasizes the importance of early identification of SRH. It also highlights that the treatment focus for SRH lies in airway management and the selection of hematoma evacuation protocols. Furthermore, it underscores the need to consider the regularity of hematoma absorption time in the retropharyngeal space, as well as the timing and approach of surgery that should be taken into account when evacuating the hematoma.
- 26 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (52) , e46846
Open AccessConservative treatment of giant spontaneous retropharyngeal hematoma: A case report
Rationale: Spontaneous retropharyngeal hematoma (SRH) is an occult disease that can cause rapid airway obstruction. Currently, no standardized diagnostic and therapeutic protocols have been established. In this case report, we present the successful conservative management of a patient with a giant SRH, further discuss strategies for airway management and hematoma evacuation, and intend to offer practical insights for the diagnosis and management of SRH. Patient concerns: A 54-year-old female patient with rapidly progressive neck swelling and respiratory tract obstruction. Diagnoses: The patient was diagnosed with SRH through computed tomography, magnetic resonance imaging, laryngoscope and ultrasound-guided aspiration biopsy. Interventions: Timely orotracheal intubation, tracheotomy, and anti-infective therapy. Outcomes: After these treatments, the patient successfully had the tracheostomy tube removed after 4 weeks and was discharged from the hospital upon recovery. Lessons: This case emphasizes the importance of early identification of SRH. It also highlights that the treatment focus for SRH lies in airway management and the selection of hematoma evacuation protocols. Furthermore, it underscores the need to consider the regularity of hematoma absorption time in the retropharyngeal space, as well as the timing and approach of surgery that should be taken into account when evacuating the hematoma.
- 2 July 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 478 (2) , 277-284
P311 knockdown alleviates hyperoxia-induced injury by inactivating the Smad3 signaling pathway in type II alveolar epithelial cells
P311 is associated with alveolar formation and development. However, the role and possible mechanism of P311 in hyperoxia-induced injury in type II alveolar epithelial cells (AEC II) need to be elucidated. In our study, rat AEC II (RLE-6TN) were exposure to normoxia (21% O2 and 5% CO2) or hyperoxia (95% O2 and 5% CO2) for 24 h, followed by determination of P311 expression. After knockdown of P311 and hyperoxic treatment, cell viability, cell cycle progression, apoptosis and the Smad3 signaling pathway were examined. Rat AEC II were pretreated with SIS3 HCl for 4 h and then subjected to P311 overexpression plasmid transfection and hyperoxic exposure. Then, cell viability, apoptosis and the Smad3 signaling pathway were determined. The results showed that hyperoxic exposure significantly elevated P311 levels in rat AEC II. P311 knockdown increased cell viability, accelerated cell cycle progression and inhibited apoptosis, as well as suppression of the Smad3 signaling pathway in hyperoxia-exposed AEC II. Additionally, we found that P311 overexpression enhanced the effects of hyperoxia. Interestingly, SIS3 HCl incubation blocked the effects of P311 overexpression on rat AEC II function under hyperoxic condition, as evidenced by an increase in cell viability, and suppressions of apoptosis and the Smad3 signaling pathway. These results indicate that P311 knockdown may ameliorate hyperoxia-induced injury by inhibiting the Smad3 signaling pathway in rat AEC II. P311 may be a novel target for the treatment of hyperoxia-induced lung injury and even bronchopulmonary dysplasia (BPD).
- 2 July 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 478 (2) , 277-284
P311 knockdown alleviates hyperoxia-induced injury by inactivating the Smad3 signaling pathway in type II alveolar epithelial cells
P311 is associated with alveolar formation and development. However, the role and possible mechanism of P311 in hyperoxia-induced injury in type II alveolar epithelial cells (AEC II) need to be elucidated. In our study, rat AEC II (RLE-6TN) were exposure to normoxia (21% O2 and 5% CO2) or hyperoxia (95% O2 and 5% CO2) for 24 h, followed by determination of P311 expression. After knockdown of P311 and hyperoxic treatment, cell viability, cell cycle progression, apoptosis and the Smad3 signaling pathway were examined. Rat AEC II were pretreated with SIS3 HCl for 4 h and then subjected to P311 overexpression plasmid transfection and hyperoxic exposure. Then, cell viability, apoptosis and the Smad3 signaling pathway were determined. The results showed that hyperoxic exposure significantly elevated P311 levels in rat AEC II. P311 knockdown increased cell viability, accelerated cell cycle progression and inhibited apoptosis, as well as suppression of the Smad3 signaling pathway in hyperoxia-exposed AEC II. Additionally, we found that P311 overexpression enhanced the effects of hyperoxia. Interestingly, SIS3 HCl incubation blocked the effects of P311 overexpression on rat AEC II function under hyperoxic condition, as evidenced by an increase in cell viability, and suppressions of apoptosis and the Smad3 signaling pathway. These results indicate that P311 knockdown may ameliorate hyperoxia-induced injury by inhibiting the Smad3 signaling pathway in rat AEC II. P311 may be a novel target for the treatment of hyperoxia-induced lung injury and even bronchopulmonary dysplasia (BPD).
- 1 August 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 97, 107675
APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma
- 1 August 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 97, 107675
APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma
- 20 July 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (2) , 1375-1390
MRP8/14 mediates macrophage efferocytosis through RAGE and Gas6/MFG‐E8, and induces polarization via TLR4‐dependent pathway
Myeloid‐related protein 8/14 (MRP8/14) participates in various inflammatory responses, however, its effect on macrophage efferocytosis remains unclear. Here, we demonstrate that MRP8/14 significantly inhibits the efferocytosis of apoptotic thymocytes by mouse bone marrow‐derived macrophages (BMDMs), which later proves to be associated with the receptor for advanced glycation end products (RAGE) or for reducing the expression of growth arrest‐specific protein 6 and milk fat globule epidermal growth factor 8, independent of RAGE. Furthermore, MRP8/14 promotes polarization of BMDMs from the M2‐ to M1‐like phenotype by upregulating expression of M1‐related surface receptor proteins and signature M1‐marker genes and by downregulating signature M2‐marker gene expression, which depends on Toll‐like receptor 4 and p38 mitogen‐activated protein kinase/nuclear factor κB pathways. Thus, we report a significant inhibitory effect of MRP8/14 on macrophage efferocytosis and MRP8/14‐mediated phenotypic polarization, which may be helpful in developing novel therapeutic strategies leading to inflammation resolution.
- 20 July 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (2) , 1375-1390
MRP8/14 mediates macrophage efferocytosis through RAGE and Gas6/MFG‐E8, and induces polarization via TLR4‐dependent pathway
Myeloid‐related protein 8/14 (MRP8/14) participates in various inflammatory responses, however, its effect on macrophage efferocytosis remains unclear. Here, we demonstrate that MRP8/14 significantly inhibits the efferocytosis of apoptotic thymocytes by mouse bone marrow‐derived macrophages (BMDMs), which later proves to be associated with the receptor for advanced glycation end products (RAGE) or for reducing the expression of growth arrest‐specific protein 6 and milk fat globule epidermal growth factor 8, independent of RAGE. Furthermore, MRP8/14 promotes polarization of BMDMs from the M2‐ to M1‐like phenotype by upregulating expression of M1‐related surface receptor proteins and signature M1‐marker genes and by downregulating signature M2‐marker gene expression, which depends on Toll‐like receptor 4 and p38 mitogen‐activated protein kinase/nuclear factor κB pathways. Thus, we report a significant inhibitory effect of MRP8/14 on macrophage efferocytosis and MRP8/14‐mediated phenotypic polarization, which may be helpful in developing novel therapeutic strategies leading to inflammation resolution.
- Open Access
- 1 January 2019
- Published by Taylor & Francis in Pathobiology of Aging & Age-related Diseases
- Vol. 9 (1) , 1647746
Rapamycin increases breast tumor burden in young wheel-running mice
Rapamycin is an immunosuppressive and anti-cancer drug recently shown to enhance healthy aging in animal models. Regular physical exercise is associated with healthy aging and reduced risk of age-related diseases, such as cancer. In order to test the combined effect of these approaches, mice with 4T1 breast cancer were fed rapamycin at 14 ppm and allowed access to voluntary running wheels. After 17 days of treatment, mice fed the rapamycin diet that ran showed a significant increase in tumor burden compared with mice that did not run (P = 0.017). Not only does this have implications for young breast cancer patients, but suggests that combining rapamycin and exercise as an anti-aging strategy at a young age might be contraindicated.
- 1 January 2019
- Published by Taylor & Francis in Pathobiology of Aging & Age-related Diseases
- Vol. 9 (1) , 1647746
Open AccessRapamycin increases breast tumor burden in young wheel-running mice
Rapamycin is an immunosuppressive and anti-cancer drug recently shown to enhance healthy aging in animal models. Regular physical exercise is associated with healthy aging and reduced risk of age-related diseases, such as cancer. In order to test the combined effect of these approaches, mice with 4T1 breast cancer were fed rapamycin at 14 ppm and allowed access to voluntary running wheels. After 17 days of treatment, mice fed the rapamycin diet that ran showed a significant increase in tumor burden compared with mice that did not run (P = 0.017). Not only does this have implications for young breast cancer patients, but suggests that combining rapamycin and exercise as an anti-aging strategy at a young age might be contraindicated.
- 3 January 2017
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 17 (4) , 369-376
Development and application of a double- antibody sandwich ELISA kit for the detection of serum MUC1 in lung cancer patients
BACKGROUND: Mucin 1 (MUC1), as an oncogene, plays an important role in the diagnosis of lung cancer. OBJECTIVE: To establish a double-antibody sandwich enzyme-linked immune sorbent assay (ELISA) kit for the detection of serum MUC1 in lung cancer pati
- 3 January 2017
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 17 (4) , 369-376
Development and application of a double- antibody sandwich ELISA kit for the detection of serum MUC1 in lung cancer patients
BACKGROUND: Mucin 1 (MUC1), as an oncogene, plays an important role in the diagnosis of lung cancer. OBJECTIVE: To establish a double-antibody sandwich enzyme-linked immune sorbent assay (ELISA) kit for the detection of serum MUC1 in lung cancer pati
- 30 November 2016
- Published by Springer Nature in Targeted Oncology
- Vol. 11 (6) , 723-738
Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development
Hepatocellular carcinoma (HCC) is among the most frequently occurring cancers and the leading causes of cancer mortality worldwide. Identification of the signaling pathways regulating liver carcinogenesis is critical for developing novel chemoprevention and targeted therapies. C-Jun N-terminal kinase (JNK) is a member of a larger group of serine/threonine (Ser/Thr) protein kinases known as the mitogen-activated protein kinase (MAPK) family. JNK is an important signaling component that converts external stimuli into a wide range of cellular responses, including cell proliferation, differentiation, survival, migration, invasion, and apoptosis, as well as the development of inflammation, fibrosis, cancer growth, and metabolic diseases. Because of the essential roles of JNK in these cellular functions, deregulated JNK is often found to contribute to the development of HCC. Recently, the functions and molecular mechanisms of JNK in HCC development have been addressed using mouse models and human HCC cell lines. Furthermore, recent studies demonstrate that the activation of JNK by oncogenes can promote the development of cancers by regulating the transforming growth factor (TGF)-beta/Smad pathway, which makes the oncogenes/JNK/Smad signaling pathway an attractive target for cancer therapy. Additionally, JNK-targeted therapy has a broad potential for clinical applications. In summary, we are convinced that promising new avenues for the treatment of HCC by targeting JNK are on the horizon, which will undoubtedly lead to better, more effective, and faster therapies in the years to come.
- 30 November 2016
- Published by Springer Nature in Targeted Oncology
- Vol. 11 (6) , 723-738
Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development
Hepatocellular carcinoma (HCC) is among the most frequently occurring cancers and the leading causes of cancer mortality worldwide. Identification of the signaling pathways regulating liver carcinogenesis is critical for developing novel chemoprevention and targeted therapies. C-Jun N-terminal kinase (JNK) is a member of a larger group of serine/threonine (Ser/Thr) protein kinases known as the mitogen-activated protein kinase (MAPK) family. JNK is an important signaling component that converts external stimuli into a wide range of cellular responses, including cell proliferation, differentiation, survival, migration, invasion, and apoptosis, as well as the development of inflammation, fibrosis, cancer growth, and metabolic diseases. Because of the essential roles of JNK in these cellular functions, deregulated JNK is often found to contribute to the development of HCC. Recently, the functions and molecular mechanisms of JNK in HCC development have been addressed using mouse models and human HCC cell lines. Furthermore, recent studies demonstrate that the activation of JNK by oncogenes can promote the development of cancers by regulating the transforming growth factor (TGF)-beta/Smad pathway, which makes the oncogenes/JNK/Smad signaling pathway an attractive target for cancer therapy. Additionally, JNK-targeted therapy has a broad potential for clinical applications. In summary, we are convinced that promising new avenues for the treatment of HCC by targeting JNK are on the horizon, which will undoubtedly lead to better, more effective, and faster therapies in the years to come.
- 1 April 2016
- Published by Elsevier in International Immunopharmacology
- Vol. 33, 108-118
Pre-clinical toxicity and immunogenicity evaluation of a MUC1–MBP/BCG anti-tumor vaccine
- 1 April 2016
- Published by Elsevier in International Immunopharmacology
- Vol. 33, 108-118
Pre-clinical toxicity and immunogenicity evaluation of a MUC1–MBP/BCG anti-tumor vaccine
- Open Access
- 14 September 2015
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 12 (5) , 6782-6788
Mucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways
Mucin 1 (MUC1) is an oncogene that has a crucial role in the pathogenesis and progression of the majority of epithelial malignant tumors. Our previous study demonstrated that MUC1 gene silencing inhibited the growth of SMMC‑7721 cells in vitro and in vivo, however, whether this growth inhibition is associated with apoptotic cell death remains to be elucidated. In the present study, it was found that MUC1 gene silencing not only resulted in the inhibition of SMMC‑7721 cell growth, determined using a clone formation assay in vitro and a tumor xenograft mouse model with an in vivo imaging system, but also induced apoptotic alterations in SMMC‑7721 cells, determined using Hoechst 33342 staining, flow cytometry with an Annexin V-PE staining and a DNA ladder assay. Further investigation using western blotting revealed that cytochrome c was released from the mitochondria into the cytoplasm, and caspase‑8 and caspase‑9 were activated in MUC1 gene‑silenced SMMC‑7721 cells. The pro‑apoptotic protein Bcl‑2‑associated X protein (Bax) and the tumor suppressor p53 were increased, while the anti‑apoptotic protein B‑cell lymphoma 2 was decreased in MUC1 gene‑silenced cells. In addition, results from the co‑immunoprecipitation experiments demonstrated that the MUC1 cytoplasmic tail can bind directly to Bax or caspase‑8 and these interactions were reduced upon MUC1 gene silencing in SMMC‑7721 cells. The above results indicate that MUC1 gene silencing induces growth inhibition in SMMC‑7721 cells through Bax‑mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways.
- 14 September 2015
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 12 (5) , 6782-6788
Open AccessMucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways
Mucin 1 (MUC1) is an oncogene that has a crucial role in the pathogenesis and progression of the majority of epithelial malignant tumors. Our previous study demonstrated that MUC1 gene silencing inhibited the growth of SMMC‑7721 cells in vitro and in vivo, however, whether this growth inhibition is associated with apoptotic cell death remains to be elucidated. In the present study, it was found that MUC1 gene silencing not only resulted in the inhibition of SMMC‑7721 cell growth, determined using a clone formation assay in vitro and a tumor xenograft mouse model with an in vivo imaging system, but also induced apoptotic alterations in SMMC‑7721 cells, determined using Hoechst 33342 staining, flow cytometry with an Annexin V-PE staining and a DNA ladder assay. Further investigation using western blotting revealed that cytochrome c was released from the mitochondria into the cytoplasm, and caspase‑8 and caspase‑9 were activated in MUC1 gene‑silenced SMMC‑7721 cells. The pro‑apoptotic protein Bcl‑2‑associated X protein (Bax) and the tumor suppressor p53 were increased, while the anti‑apoptotic protein B‑cell lymphoma 2 was decreased in MUC1 gene‑silenced cells. In addition, results from the co‑immunoprecipitation experiments demonstrated that the MUC1 cytoplasmic tail can bind directly to Bax or caspase‑8 and these interactions were reduced upon MUC1 gene silencing in SMMC‑7721 cells. The above results indicate that MUC1 gene silencing induces growth inhibition in SMMC‑7721 cells through Bax‑mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways.
- 1 June 2015
- Published by Elsevier in Immunobiology
- Vol. 220 (6) , 782-788
Escherichia coli maltose-binding protein (MBP) directly induces mouse Th1 activation through upregulating TLR2 and downregulating TLR4 expressions
- 1 June 2015
- Published by Elsevier in Immunobiology
- Vol. 220 (6) , 782-788
Escherichia coli maltose-binding protein (MBP) directly induces mouse Th1 activation through upregulating TLR2 and downregulating TLR4 expressions